Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 2/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922665 | 0.79 | AHR (0.51) | MAPTTDP2PARP1MEN1KMT2A | |
| SCHEMBL4847672 | 0.79 | MAOA (0.40) | RAB9AMAPTTDP2MAPKAPK2ALDH1A1 | |
| SCHEMBL542110 | 0.79 | TDP2 (0.49) | HSD17B10LMNASMN1; SMN2MAPTTDP2 | |
| SCHEMBL29408741 | 0.75 | MAOA (0.48) | CASP7SMN1; SMN2NPC1GAATDP2 | |
| SCHEMBL6937 | 0.75 | MAOA (0.48) | CASP7SMN1; SMN2NPC1GAATDP2 | |
| SCHEMBL531586 | 0.75 | TDP2 (0.49) | HSD17B10MAPTGAACA9TDP2 | |
| SCHEMBL8623559 | 0.75 | GAA (0.50) | RAB9ASMN1; SMN2NPC1MAPTGAA | |
| SCHEMBL182798 | 0.73 | TDP2 (0.54) | LMNARAB9AMAPTTDP2GRIA2 | |
| Hydrochloric Acid SCHEMBL5625931 | 0.73 | MAOA (0.46) | CASP7SMN1; SMN2NPC1GAATDP2 | |
| SCHEMBL2919635 | 0.73 | MAOA (0.46) | CASP7SMN1; SMN2NPC1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112795343-B | High-adhesion epoxy resin pouring sealant and application method thereof | 台州腾标电子有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-112724900-B | Tough epoxy resin adhesive and preparation method thereof | 台州腾标电子有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-112724900-B | Tough epoxy resin adhesive and preparation method thereof | 台州腾标电子有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-112795343-A | High-adhesion epoxy resin pouring sealant and application method thereof | 台州腾标电子有限公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-112724900-A | Tough epoxy resin adhesive and preparation method thereof | 台州腾标电子有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112724900-A | Tough epoxy resin adhesive and preparation method thereof | 台州腾标电子有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-9975862-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | REVIVA PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9604944-B2 | Arylpiperazine derivatives and methods of utilizing same | REVIVA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2400968-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING ARYLPIPERAZINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-09-28 | — | — | EP | disclosed |
| US-20070259946-A1 | N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7247625-B2 | 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | LIGAND PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH | 2005-04-21 | — | — | US | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327477-A1 | ARYLPIPERAZINE DERIVATIVES AND METHODS OF UTILIZING SAME | GRIK5, HTR5A, GRIK2 | CASP1 2016/4885CASP7 2030/4885HSD17B10 351/4885 |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | FSHR, CYP19A1, ESR2 | CASP1 4681/4885CASP7 3781/4885HSD17B10 504/4885 |
| US-20070259946-A1 | N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane | TRPV1, TRPV5, TRPA1 | CASP1 1079/4885CASP7 2701/4885HSD17B10 4686/4885 |
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | CASP1 3905/4885CASP7 859/4885HSD17B10 419/4885 |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | CASP1 3905/4885CASP7 859/4885HSD17B10 419/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | CASP1 4498/4885CASP7 4463/4885HSD17B10 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.